Effect of nonsurgical periodontal therapy verses oral hygiene instructions on Type 2 diabetes subjects with chronic periodontitis: a randomised clinical trial


40 subjects with type 2 diabetes and moderate to severe CP were randomly distributed to groups receiving either NSPT or OHI. Periodontal parameters, glycosylated haemoglobin (HbA1c) and high-sensitivity C-reactive protein (hs-CRP) were evaluated at baseline, 2- and 3-months intervals.

Methods: 40 subjects with type 2 diabetes and moderate to severe CP were randomly distributed to groups receiving either NSPT or OHI.

Periodontal parameters, glycosylated haemoglobin (HbA1c) and high-sensitivity C-reactive protein (hs-CRP) were evaluated at baseline, 2- and 3-months intervals.

Results: 15 subjects from NSPT group and 17 from OHI group completed the study. The difference in plaque index (PI) between NSPT and OHI groups were significant at 2 months recall (p = 0.013).

There was no significant difference between NSPT and OHI group for all other clinical periodontal parameters, HbA1c and CRP levels. At 3 months post-therapy, periodontal parameters improved significantly in both groups with sites with probing pocket depth (PPD) <4 mm reported as 98 +/- 1.8% in NSPT group and 92 +/- 14.9% in OHI group.

Mean PPD and mean probing attachment loss (PAL) within the NSPT group reduced significantly from baseline (2.56 +/- 0.57 mm, 3.35 +/- 0.83 mm) to final visit (1.94 +/- 0.26 mm, 2.92 +/- 0.72 mm) (p = 0.003, p <0.001). For OHI group, improvements in mean PPD and mean PAL were also seen from baseline (2.29 +/- 0.69 mm, 2.79 +/- 0.96 mm) to final visit (2.09 +/- 0.72 mm, 2.62 +/- 0.97 mm) (p <0.001 for both).

Similarly, HbA1c levels decreased in both groups with NSPT group recording statistically significant reduction (p = 0.038). Participants who demonstrated >= 50% reduction in PPD showed significant reductions of HbA1c and hs-CRP levels (p = 0.004 and p = 0.012).

Conclusion: NSPT significantly reduced PI at 2 months post-therapy as compared to OHI.

Both NSPT and OHI demonstrated improvements in other clinical parameters as well as HbA1c and CRP levels.Trial registration: ClinicalTrials.gov: NCT01951547.



Published on: 2014-06-25

Made available by EUPB via SpringerOpen / BioMedCentral. Please make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. To submit your press release click here.

Discussions




Custom Search



Username
Password










© 2017 7thSpace Interactive
All Rights Reserved - About | Disclaimer | Helpdesk